PCAS key Figures (2015)

€179.1

million


Consolidated net sales

6.7%


Of net sales dedicated to R&D

7


Production sites

€27

million


EBITDA
Earnings before interest, taxes, depreciation and amortization

8.5%


Of net sales dedicated to industrial investments

916


Employees

PCAS sales
/ by geographic zone /

  • 34.83%
    Europe
  • 32.61%
    France
  • 16.42%
    Asian Pacific
  • 12.01%
    North America
  • 4.13%
    Others

PCAS sales
/ by market /

  • 40.83%
    Pharma Synthesis Exclusive & Pharma Chemicals
  • 26.61%
    Pharma Sythesis Generic APls
  • 17.33%
    Performance Fine Chemicals
  • 15.33%
    Advanced Specialties

Breakdown of PCAS
Share Capital at
12/31/2015

  • 44.7%
    Public
  • 29.4%
    Eximium
  • 14.7%
    C. Moretti / Anblan
  • 9.8%
    Treasury stocks*
  • 1.4%
    Management

(*) excluding 1966 treasury shares as part of a liquidity contract

In millions of euros20142015
Net sales166.4179.1
Pharmaceutical synthesis
Fine specialty chemicals
108.1
58.3
120.8
58.3
EBITDA*18.327.0
EBITDA margin11.0%15.1%
Current operating income*8.015.6
Other operating income and expenses
Financial result
Taxes
Share of profit / loss of associates
-2.1
-3.3
-0.1
-0.1
0.4
-5.1
-2.1
-
Net profit attributable to the Group2.59.0
Equity
Net debt
80.2
48.0
89.1
34.7
Gearing0.600.39
Net asset attributable to the Group per share5.826.41

*Including research tax credit of €3.1 million in 2015 and 2014.

Key adjusted per share figures

In euros201320142015
Highest price4.124.778.00
Lowest price2.823.513.60
Price at the end of December3.583.747.97
Net sales10.9110.9911.83
Current operating income0.550.531.03
Net profit attributable to the Group0.230.170.59

PCAS shares are listed on Nyse Euronext, compartment C. The shares have been continuously listed since October 17, 1996 and are subject to a liquidity contract with Kepler Cheuvreux.

PCAS 2015 share price

8.00
7.00
6.00
5.00
4.00
3.00
JanFebMarAprMayJunJulAugSepOctNovDec
-PCAS-CAC MID & SMALL-CAC 40

Contacts: